< Back to all Breaking News
APOP
10/15/2018 07:10am
Cellect Biotechnology reports safety data from Phase I/II trial of ApoGraft
Don't miss out!
We read the Wall Street research, SEC filings and press releases so you don't have to.
Sign up for our 14-day free trial to read this story.